Mevlüt Karataş | Pulmonary | Best Researcher Award

Published on by Academic Awards

Assoc Prof Dr. Mevlüt Karataş | Pulmonary | Best Researcher Award

Assoc Prof Dr. Mevlüt Karataş, SBU Ataturk Sanatorium Education and Training Hospital, Turkey

Dr. Mevlüt Karataş is an Associate Professor specializing in pulmonary diseases. He earned his Bachelor’s Degree from Istanbul University, Cerrahpasa School of Medicine (1994-2001), and completed his specialization at Istanbul Fatih Sultan Mehmet Training and Research Hospital. Dr. Karataş conducted research at Vanderbilt University School of Medicine with Prof. Dr. Richard Light in 2007. He served as a Specialist Physician at several hospitals, including Ahi Evren Chest Cardiovascular Surgery Training and Research Hospital, Kanuni Training and Research Hospital, and Atatürk Chest Diseases and Surgery Training and Research Hospital. He became an Associate Professor at the University of Health Sciences in 2021. 📚🏥

Publication Profile

Orcid

Education 🎓

Dr. Mevlüt Karataş earned his Bachelor’s Degree from Istanbul University, Cerrahpasa School of Medicine (1994-2001). He specialized in medicine at Istanbul Fatih Sultan Mehmet Training and Research Hospital (2003-2009), with a thesis on tuberculosis. In 2007, he was a Research Fellow at Vanderbilt University School of Medicine, working with Prof. Dr. Richard Light on pleural diseases.

Professional Background 🏥

Dr. Karataş has served as a Specialist Physician at Ahi Evren Chest Cardiovascular Surgery Training and Research Hospital (2009-2011), Kanuni Training and Research Hospital (2011-2014), and Atatürk Chest Diseases and Surgery Training and Research Hospital (2017-2024).

Certificate 📜

Dr. Karataş received the ILO International Pneumoconiosis Radiographs Classification Training Certificate in 2018, enhancing his expertise in evaluating pneumoconiosis cases.

 

Research Focus

Assoc. Prof. Dr. Mevlüt Karataş’s research primarily focuses on pulmonary and respiratory health, particularly in the context of occupational and environmental exposures. His work includes studying allergenic pollen in Trabzon, assessing oxidative stress markers in workers, and evaluating the impact of obstructive sleep apnea on ocular health. He has also investigated the effectiveness of chest CT in COVID-19 triage and explored the progression of silicosis among ceramic workers. His research spans antibiotic resistance in respiratory pathogens and endobronchial management of airway obstructions, reflecting a broad interest in respiratory diseases and their management. 🌿🫁🦠

 

Publication Top Notes

  • “Trabzon İli Atmosferindeki Alerjenik Polenlerin Volumetrik Yöntemle Belirlenmesi” – Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 2022. DOI: 10.21597/jist.1082302 🌿
  • “Dynamic thiol disulfide homeostasis in painters as indices of oxidative stress” – International Journal of Environmental Health Research, 2022. DOI: 10.1080/09603123.2020.1827227 🔬
  • “In COVID-19 Suspicion Without Severe Manifestations, Chest CT Sensitivity is not Sufficient for Triage: A Single-centre Experience” – Journal of Ankara University Faculty of Medicine, 2021. DOI: 10.4274/atfm.galenos.2021.93723 🦠
  • “Effects of Obstructive Sleep Apnea Syndrome on the Eye” – Hamidiye Medical Journal, 2021. DOI: 10.4274/hamidiyemedj.galenos.2020.35220 👁️
  • “ANTIBIOTIC RESISTANCE AND INTEGRON GENE CASSETTES IN ACINETOBACTER BAUMANNII ISOLATES PRODUCED IN LOWER RESPIRATORY TRACT SAMPLES TAKEN FROM THE INTENSIVE CARE UNIT” – Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 2020. DOI: 10.24938/kutfd.789547 🦠
  • “Dynamic thiol/disulphide homeostasis as indicator of oxidative stress in automotive workers” – Biomarkers, 2020. DOI: 10.1080/1354750X.2020.1734862 🚗
  • “Endobronchial management of malignant central airway obstruction: the first 6-year single center experience” – The European Research Journal, 2019. DOI: 10.18621/eurj.556443 🌬️
  • “Predictive risk factors for development of silicosis in Turkish ceramic workers” – Tuberkuloz ve Toraks, 2019. DOI: 10.5578/tt.67990 ⚠️
  • “Radiological progression and lung function decrements among silica-exposed ceramic workers: a longitudinal study” – Inhalation Toxicology, 2019. DOI: 10.1080/08958378.2019.1613459 🏭

Ulrica Scaffidi Argentina | Respiratory Medicine | Excellence in Research

Published on by Academic Awards

Dr. Ulrica Scaffidi Argentina | Respiratory Medicine | Excellence in Research

Dr. Ulrica Scaffidi Argentina,Chiesi Italia s.p.a, Italy

👩‍⚕️ Dr. Ulrica Scaffidi Argentina 🇮🇹 is a dynamic medical professional with a robust scientific background. Currently serving as a Medical Advisor in the Respiratory Area at Chiesi Italia S.p.a., she has extensive experience in medical liaison roles and clinical practice. Her expertise spans orthopedic oncology, radiology, and clinical research, with a focus on respiratory and immunology fields. Driven by passion and dedication, she actively contributes to medical advancements, evident through her publications and presentations at national and international conferences. 🌟

Publication Profile:

Google Scholar

Education and Qualification :

🎓 Dr. Ulrica Scaffidi Argentina’s educational journey is marked by excellence and dedication. She earned her Master’s Degree in Medicine and Surgery from LA SAPIENZA University in 2017, focusing on adult scoliosis in her thesis under the guidance of Prof. Giuseppe Costanzo. As a qualified Medical Surgeon, she is registered with the Order of Surgeons and Dentists. Additionally, her degree in Medical Radiology Technician from LA SAPIENZA University showcases her proficiency in imaging and radiotherapy. Her commitment to professional development is evident through her completion of the Clinical Project Management course in 2020, enhancing her skills in clinical research and project management. 🌟

Professional Experience :

👩‍⚕️ Dr. Ulrica Scaffidi Argentina has showcased her expertise across various roles in the medical field. As a Medical Advisor in the Respiratory Area at Chiesi Italia S.p.a., she plays a pivotal role in shaping strategies for respiratory and primary care in Italy. Prior to this, she served as a Medical Science Liaison, specializing in respiratory and immunology areas, demonstrating her versatility and knowledge. With a stint as a Medical Doctor at the Regina Elena National Cancer Institute in Rome, she contributed significantly to oncological orthopedics, engaging in clinical, surgical, and research endeavors. Her journey reflects a deep commitment to advancing healthcare and combating diseases. 🌟

Certificates :

📜 Dr. Ulrica Scaffidi Argentina’s linguistic prowess is evident through her language certifications. She obtained an English course certificate from CLL in Brussels in August 2013 and another from Dublin in July 2000. Her proficiency in Spanish is showcased by the Initial Spanish Certificate (D.E.L.E.) from the Instituto Cervantes in July 2002, along with an Advanced Spanish course certification from the University of Salamanca in March 2003. These certifications highlight her dedication to mastering languages, fostering effective communication across diverse cultural landscapes. 🌍🌟

Research Focus:

The individual’s research focus appears to center around respiratory diseases, particularly idiopathic pulmonary fibrosis (IPF) and related interstitial lung diseases (ILDs). Their work includes the development of evidence-based guidelines for diagnosis and management of IPF, as well as assessing the efficacy and safety of therapeutic interventions such as nintedanib. Additionally, they contribute to updating classification systems for ILDs and guidelines for the treatment of IPF. This research is crucial in advancing understanding, diagnosis, and treatment options for patients with these debilitating respiratory conditions. 🩺 Their efforts contribute significantly to improving patient care and outcomes in the field of respiratory medicine.

Publication Top Notes:

  1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management 📚 Cited by 8666, Year: 2011
  2. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 📚 Cited by 4263, Year: 2014
  3. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias📚 Cited by 3685, Year: 2013
  4. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline📚 Cited by 3012, Year: 2018
  5. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society 📚 Cited by 1877, Year: 2020
  6. Nintedanib in progressive fibrosing interstitial lung diseases 📚 Cited by 1672, Year: 2019
  7. Allergenic pollen and pollen allergy in Europe 📚 Cited by 1580, Year: 2017
  8. Idiopathic pulmonary fibrosis📚 Cited by 1401, Year: 2017
  9. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline 📚 Cited by 1389, Year: 2015
  10. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis📚 Cited by 1293, Year: 2011